Zykadia, or ceritinib, is from a new class medicines known as ALK
inhibitors. It was approved in April 2014 in the United States.
It is designed for use in non-small cell lung cancer patients who
have previously been treated with Pfizer's Xalkori, another ALK
inhibitor.
Between 2 and 7 percent of non-small cell lung cancer patients have
the specific mutation of the ALK (anaplastic lymphoma kinase)
protein for which such treatment is targeted. They are often non
smokers.
(Reporting by Ben Hirschler)
[to top of second column] |
![](../images/ads/current/Symphony_122313.png)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |